<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Optimization of HDAC Inhibitors for HCC

Hepatocellular carcinoma (HCC) is among the leading causes of cancer death worldwide, with poor overall survival rates and limited efficacy of standard of care agents. There is, therefore, a high unmet need to identify new targets and corresponding drug candidates for HCC.